IL6 and heart failure: Further, a small clinical trial (NCT03727646) for oral nicotinamide riboside in patients with heart failure demonstrated that 5–9 days of treatment reduced PBMC cytokine production, including IL-6, suggesting that nicotinamide-based treatments can rapidly reduce systemic inflammation, a known risk factor for postoperative AKI [29].